Gamal Ahmed, Moschovas Marcio C, Jaber Abdel R, Saikali Shady, Reddy Sumeet, Kunta Avaneesh, Sandri Marco, Rogers Travis, Patel Vipul
AdventHealth Global Robotics Institute, Celebration, Florida, USA.
University of Central Florida (UCF), Orlando, Florida, USA.
Prostate. 2025 Apr;85(5):456-462. doi: 10.1002/pros.24848. Epub 2024 Dec 29.
Robotic-assisted radical prostatectomy (RARP) is widely used as the main surgical approach to treat prostate cancer in the United States. Prostate size is often described as a factor affecting the outcomes of RARP as shown by many studies. However, these studies are limited to a small number of patients.
To evaluate the functional and oncologic outcomes of RARP in very large prostate sizes.
Three hundred and seventy-five RARP patients were divided into two groups according to prostate size: Group 1 had prostates larger than 150 g and Group 2 smaller than 50 g. Perioperative variables were matched with propensity score matching 1:3 and postoperative variables were analyzed for significant differences in outcomes between groups. Variables analyzed included estimated blood loss (EBL), operative time, catheter time, hospitalization time, postoperative complications, pathological staging, positive surgical margins (PSM) rates, biochemical recurrence (BCR), potency, and continence rates.
The two groups exhibited similar preoperative characteristics. Patients with larger prostates (Group 1) were more likely to have higher blood loss (EBL), longer console time, and more days with catheter. However, we could not find significant difference in the overall postoperative complications (Clavien-Dindo). Pathological outcomes were also statistically different as patients with larger prostates had (69.7%) more pT2 disease and (12.1%) lower rates of PSM. Finally, we could not find significant difference in the functional outcomes between the groups.
The results demonstrate that prostate size impacts multiple outcomes. Larger prostates had lower-grade disease, reduced EPE and PSM rates, with no significant differences in BCR or functional outcomes. Perioperative differences, such as increased blood loss and console time, were also observed.
机器人辅助根治性前列腺切除术(RARP)在美国被广泛用作治疗前列腺癌的主要手术方法。许多研究表明,前列腺大小常被描述为影响RARP手术结果的一个因素。然而,这些研究仅限于少数患者。
评估RARP在前列腺体积非常大的患者中的功能和肿瘤学结果。
375例RARP患者根据前列腺大小分为两组:第1组前列腺大于150g,第2组小于50g。采用倾向评分匹配1:3对围手术期变量进行匹配,并分析术后变量以比较两组间结果的显著差异。分析的变量包括估计失血量(EBL)、手术时间、导尿管留置时间、住院时间、术后并发症、病理分期、手术切缘阳性(PSM)率、生化复发(BCR)、性功能和控尿率。
两组术前特征相似。前列腺较大的患者(第1组)更可能有更高的失血量(EBL)、更长的控制台操作时间和更多的导尿管留置天数。然而,我们未发现总体术后并发症(Clavien-Dindo分级)有显著差异。病理结果在统计学上也有差异,因为前列腺较大的患者有更多的pT2期疾病(69.7%)和更低的PSM率(12.1%)。最后,我们未发现两组间功能结果有显著差异。
结果表明前列腺大小会影响多个结果。较大的前列腺疾病分级较低,包膜外侵犯(EPE)和PSM率降低,BCR或功能结果无显著差异。还观察到围手术期的差异,如失血量增加和控制台操作时间延长。